RLYB
Rallybio Corp
NASDAQ: RLYB · HEALTHCARE · BIOTECHNOLOGY
$8.98
+1.13% today
Updated 2026-04-30
Market cap
$46.55M
P/E ratio
—
P/S ratio
54.25x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$2 – $11
Volume
0.2M
Rallybio Corp (RLYB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $636000.00 | $858000.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | +34.9% |
| Cost of revenue | $26344.00 | $62030.00 | $109000.00 | $167000.00 | $150000.00 | $131000.00 | $92000.00 |
| Gross profit | $-26344.00 | $-62030.00 | $-109000.00 | $-167000.00 | $-150000.00 | $636000.00 | $766000.00 |
| Gross margin | — | — | — | — | — | 100.0% | 89.3% |
| R&D | $11.37M | $17.63M | $26.91M | $40.69M | $53.54M | $41.51M | $19.60M |
| SG&A | $6.28M | $7.67M | $18.74M | $27.20M | $25.39M | $19.63M | $14.32M |
| Operating income | $-17.64M | $-25.30M | $-45.65M | $-67.88M | $-78.93M | $-60.50M | $-28.06M |
| Operating margin | — | — | — | — | — | -9511.9% | -3270.9% |
| EBITDA | $-17.39M | $-25.24M | $-45.39M | $-67.72M | $-78.78M | $-60.37M | $-27.97M |
| EBITDA margin | — | — | — | — | — | -9491.4% | -3260.1% |
| EBIT | $-17.42M | $-25.30M | $-45.50M | $-67.88M | $-78.93M | $-60.50M | $-28.06M |
| Interest expense | $39000.00 | $49000.00 | $10000.00 | $2.31M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.63M | $-26.45M | $-47.01M | $-66.65M | $-74.56M | $-57.77M | $-8.98M |
| Net income growth (YoY) | — | -50.0% | -77.8% | -41.8% | -11.9% | +22.5% | +84.5% |
| Profit margin | — | — | — | — | — | -9084.1% | -1046.4% |